| Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.BMC Cancer | PMID 37838670PMC10576321 | 2023-Oct-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial.Clin Infect Dis | PMID 37232940PMC10573726 | 2023-Oct-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).Clin Infect Dis | PMID 37338158PMC10573722 | 2023-Oct-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.Clin Cancer Res | PMID 37581616PMC10570675 | 2023-Oct-13 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.N Engl J Med | PMID 37754204无 PMCID | 2023-Oct-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.BMC Health Serv Res | PMID 37821934PMC10568806 | 2023-Oct-11 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.J Clin Oncol | PMID 37335960无 PMCID | 2023-Oct-10 | 0.95 | The study is a randomized Phase III trial in AML with time-to-event endpoints, but the intervention is a transplant conditioning regimen (BuFlu vs. BuCy) and the primary endpoint is TRM, not a primary efficacy endpoint for cancer treatment (e.g., OS, PFS). Drug intervention for malignancy is not established. | 待处理 |
| Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.J Clin Oncol | PMID 37506329PMC10564308 | 2023-Oct-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial.BMC Med | PMID 37814306PMC10563289 | 2023-Oct-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.Lancet | PMID 37708904PMC11664154 | 2023-Oct-07 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.Clin Infect Dis | PMID 37279602PMC10552586 | 2023-Oct-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.Blood | PMID 37366170PMC10644097 | 2023-Oct-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.N Engl J Med | PMID 37792612无 PMCID | 2023-Oct-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.N Engl J Med | PMID 37792613无 PMCID | 2023-Oct-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial.BMC Res Notes | PMID 37798748PMC10557307 | 2023-Oct-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Short-term outcomes of Early versus conventional adjuvant chemotherapy in stage III colon cancer: randomized clinical trial.BJS Open | PMID 37439066PMC10338899 | 2023-Oct-03 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.Oncologist | PMID 37665777PMC10546816 | 2023-Oct-03 | 0.45 | The report is from a Phase III randomized trial in oncology with a drug intervention, but the abstract focuses exclusively on cardiac safety (LVEF) data and does not report any time-to-event efficacy endpoint (e.g., OS, PFS). | 待处理 |
| Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study.J Am Heart Assoc | PMID 37753718PMC10727262 | 2023-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.Sci Rep | PMID 37789040PMC10547846 | 2023-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.J Clin Invest | PMID 37561579PMC10541188 | 2023-Oct-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Virologic response to antiretroviral therapy in people with HIV and tuberculosis in high tuberculosis burden countries.AIDS | PMID 36928120无 PMCID | 2023-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial.Int J Radiat Oncol Biol Phys | PMID 37087060无 PMCID | 2023-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys | PMID 37137444PMC10949135 | 2023-Oct-01 | 0.90 | The report is a secondary analysis of a genomic classifier in a Phase III randomized trial of radiation therapy doses. While it meets oncology, human, randomized, phase, and time-to-event criteria, it lacks a drug-containing intervention. The intervention is non-drug (radiation therapy), and the analysis is focused on a biomarker (genomic classifier) rather than being the original report of a drug trial. | 待处理 |
| Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer.JAMA Surg | PMID 37466971PMC10357358 | 2023-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial.JAMA Neurol | PMID 37578800PMC10425876 | 2023-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.JAMA Neurol | PMID 37603328PMC10442780 | 2023-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety.Pediatrics | PMID 37667847无 PMCID | 2023-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.JAMA Neurol | PMID 37695623PMC10495927 | 2023-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial.Clin J Am Soc Nephrol | PMID 37696667PMC10578632 | 2023-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma.Indian J Cancer | PMID 38185869无 PMCID | 2023-Oct-01 | 0.85 | The study is a Phase III randomized trial of drug-containing regimens in human oncology, but the primary endpoint is complete response (CR), which is not a time-to-event outcome. The abstract does not report any time-to-event endpoints (OS, PFS, DFS, etc.), Kaplan-Meier analyses, or hazard ratios. | 待处理 |
| A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.Child Psychiatry Hum Dev | PMID 35292925无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.Infection | PMID 36648627PMC9844162 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).Cancer Res Treat | PMID 37232070PMC10645518 | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.Lancet Respir Med | PMID 37244266无 PMCID | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.J Eur Acad Dermatol Venereol | PMID 37262309无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.Clin Genitourin Cancer | PMID 37263910无 PMCID | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).Ophthalmology | PMID 37285925无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.Lancet Infect Dis | PMID 37302406PMC11259948 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.J Eur Acad Dermatol Venereol | PMID 37319109无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS©): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial.Qual Life Res | PMID 37347393PMC10474203 | 2023-Oct | 0.95 | The record describes a secondary analysis evaluating the psychometric properties of a patient-reported outcome tool (GODDESS©) from the Phase 3 DeFi trial. While it is an oncology, human, randomized, Phase 3 trial with a drug intervention and reports original results, it does not present the primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) required for this cohort. The deterministic review correctly identified 'no_time_to_event_signal'. | 待处理 |
| Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.Lancet Infect Dis | PMID 37352880无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: Results from two phase 3 double-blind, randomized, vehicle-controlled studies.J Am Acad Dermatol | PMID 37356627无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results.Clin Pharmacol Ther | PMID 37365904PMC10851912 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.Allergy | PMID 37366581无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study.Respir Med | PMID 37392789无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.Diabetes Obes Metab | PMID 37402696无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.Clin Breast Cancer | PMID 37423801无 PMCID | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.Ann Oncol | PMID 37467930无 PMCID | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.Clin Lymphoma Myeloma Leuk | PMID 37479547无 PMCID | 2023-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma.Eur J Nucl Med Mol Imaging | PMID 37493665PMC10547616 | 2023-Oct | 0.90 | The record is from a phase III randomized controlled trial in multiple myeloma, but this specific abstract reports only on the validation of an AI tool for PET/CT assessment of bone marrow involvement, correlating with histopathological and clinical parameters. It does not report any survival, progression, recurrence, death, hazard, time-to-event, or other efficacy outcomes from the trial. | 待处理 |